B.Riley initiates Neuronetics stock coverage with buy rating

B. Riley initiated Neuronetics (NASDAQ: STIM) at Buy with a $5 target, implying roughly 66% upside from $3.01, citing Greenbrook-driven growth, operating leverage and a potential re-rating toward peer valuation multiples. Q2 revenue rose 9% year over year to $41.6M, above $40.2M consensus, while adjusted EBITDA turned positive at $0.3M versus expectations for a $3.7M loss; gross margin expanded 1,450bps to 61.1%. Greenbrook revenue increased 16.8% to $26.9M, offsetting a 2.7% decline in NeuroStar revenue, and BTIG subsequently raised its target to $6 while maintaining Buy.

Analysis

STIM’s investable question is no longer whether the clinic footprint can grow, but whether management can convert that footprint into durable cash generation after integration costs, reimbursement friction, and debt servicing. The earnings inflection is highly sensitive to clinic utilization and collections: incremental visits should carry high contribution margins, but a reversal in denial rates or clinician labor inflation would expose the operating leverage in the opposite direction. The device segment’s softness also matters more than headline consolidated growth implies; sustained contraction would weaken the strategic claim that STIM has both recurring clinic economics and a scalable equipment channel.

The market is likely to price a clean leverage-and-liquidity resolution before assigning value to any longer-dated psychedelic adjacency. A single quarter of positive adjusted EBITDA is insufficient evidence for a multiple re-rate in a thinly traded small cap, particularly where working-capital timing and revenue-cycle improvements can flatter near-term results. Over the next 1-3 months, covenant disclosures, cash burn, clinic same-store growth, and EBITDA conversion are the relevant catalysts; over 6-18 months, payer coverage expansion and sustained utilization could create a credible platform premium versus pure-play TMS peer BrainsWay (BWAY).

Contrarian view: the sell-side targets may understate the value of fixed-cost absorption if acquired clinics reach normalized utilization, but the stock’s sharp run means execution is no longer free. Psychedelic approvals are not a near-term earnings catalyst for STIM and could ultimately introduce new treatment modalities that compete for psychiatric capital budgets rather than simply expand demand. The thesis is falsified by renewed negative adjusted EBITDA, declining clinic revenue per location, or any covenant amendment that requires dilutive equity issuance.

Key Decisions for Investors

• Do not chase STIM after the momentum move; establish only on a pullback toward $2.50-$2.70 or after the next report confirms positive adjusted EBITDA with positive operating cash-flow trajectory. Target $4.50-$5.00 over 6-12 months; exit if quarterly adjusted EBITDA falls below negative $2 million or liquidity/covenant language deteriorates.
• For a higher-risk small-cap sleeve, use a defined-risk STIM position sized at no more than half a normal biotech allocation until net-debt, covenant headroom, and post-acquisition cash conversion are independently verified. The upside case requires multiple expansion alongside execution; the downside includes substantial dilution risk.
• Monitor a relative-value long STIM / short BWAY only after STIM demonstrates two consecutive quarters of positive EBITDA and stable device revenue. The pair isolates clinic-utilization and integration upside, but should be avoided if BWAY’s international growth accelerates or STIM’s receivables rise faster than revenue.
• Treat CMPS/ATAI regulatory milestones as sentiment alerts rather than direct STIM catalysts. A favorable psychedelic decision could improve interventional-psychiatry investor flows, but no position should underwrite material STIM revenue before payer reimbursement, provider training, and patient-routing economics are observable.